Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 12
Submit an article Journal homepage
855
Views
8
CrossRef citations to date
0
Altmetric
Original Articles

Chronic myeloid leukemia presenting in lymphoblastic crisis, a differential diagnosis with Philadelphia-positive B-lymphoblastic leukemia

Zhining Chena Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;b Department of Pathology, Affiliated Tumor Hospital, Guangxi Medical University, Nanning, China
,
Shimin Hua Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
Sa A. Wanga Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
Marina Konoplevac Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
Zhenya Tanga Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
Jie Xua Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
Shaoying Lia Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
Gokce Torunera Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
Beenu Thakrala Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
L. Jeffrey Medeirosa Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
&
Guilin Tanga Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9482-4806
ORCID Icon show all
Pages 2831-2838 | Received 17 Apr 2020, Accepted 05 Jul 2020, Published online: 23 Jul 2020

References

  • Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841–851.
  • Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–1054.
  • Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–2340.
  • Jain P, Kantarjian HM, Ghorab A, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients. Cancer. 2017;123(22):4391–4402.
  • Vardiman JW, Melo JV Baccarabu M, et al. Chronic myeloid leukemia, BCR-ABL1-positive. In: Swerdlow S, Campo E, Harris N, al e, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th edition. Lyon: International Agency for Research on Cancer (IARC); 2017. p. 30–36.
  • Borowitz MJ, Chan JKC, Downing JR, et al. B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities. In: Swerdlow S, Campo E, Harris N, al e, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues,. Revised 4th edition. Lyon: International Agency for Research on Cancer (IARC); 2017. p.203–204.
  • Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009;113(8):1619–1630.
  • Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88(7):2375–2384.
  • Cimino GP, Elia L. The role of BCR-ABL isoforms in the presentation and outcome of patients with philadelphia-positive acute lymphoblastic leukemia. Haematologica. 2006;91(3):377–380.
  • Melo JV, Myint H, Galton DA, et al. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia. 1994;8(1):208–211.
  • Tang G, Sydney Sir Philip JK, Weinberg O, et al. Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study. Mod Pathol. 2019;32(4):490–498.
  • Jaso J, Thomas DA, Cunningham K, et al. Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors. Cancer. 2011;117(17):4009–4017.
  • Kamoda Y, Izumi K, Iioka F, et al. Philadelphia chromosome-positive acute lymphoblastic leukemia is separated into two subgroups associated with survival by bcr-abl fluorescence in situ hybridization of segmented cell nuclei: report from a single institution. Acta Haematol. 2016;136(3):157–166.
  • Raanani P, Trakhtenbrot L, Rechavi G, et al. Philadelphia-chromosome-positive T-lymphoblastic leukemia: acute leukemia or chronic myelogenous leukemia blastic crisis. Acta Haematol. 2005;113(3):181–189.
  • Balducci E, Loosveld M, Rahal I, et al. Interphase FISH for BCR-ABL1 rearrangement on neutrophils: a decisive tool to discriminate a lymphoid blast crisis of chronic myeloid leukemia from a de novo BCR-ABL1 positive acute lymphoblastic leukemia. Hematol Oncol. 2018;36(1):344–348.
  • Kolenova A, Maloney KW, Hunger SP. Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in lymphoid blast crisis. J Pediatr Hematol Oncol. 2016;38(6):e193–e195.
  • Nicolini FE, Basak GW, Kim DW, et al. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 2017;123(15):2875–2880.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.